<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049944</url>
  </required_header>
  <id_info>
    <org_study_id>186-13</org_study_id>
    <nct_id>NCT02049944</nct_id>
  </id_info>
  <brief_title>Increased Cefazolin During Cesarean Delivery in Obese Population</brief_title>
  <official_title>Increased Cefazolin (Ancef) Dosing for Prophylaxis During Cesarean Delivery in the Obese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MemorialCare Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MemorialCare Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an increased prophylactic dose (3 grams) of&#xD;
      cefazolin at the time of cesarean delivery has superior coverage in adipose tissue than the&#xD;
      current established dosing of 2 grams. The tissue and serum concentration values, when using&#xD;
      an increased prophylactic dose, can then be compared to our pilot study assays in hopes of&#xD;
      determining an optimal dosing for the obese and morbidly obese populations undergoing&#xD;
      cesarean delivery.&#xD;
&#xD;
      A previous study performed at University of California, Irvine (UCI) and Long Beach Memorial&#xD;
      Medical Center/Miller Children's Hospital (LBMMC) showed that the standard dose of&#xD;
      antibiotics (2 grams of cefazolin) did not provide adequate coverage for all organisms in the&#xD;
      obese and extremely obese populations. The purpose of this research study is to evaluate&#xD;
      whether in increased dose of antibiotics given before cesarean delivery (3 grams of&#xD;
      cefazolin) will reach adequate levels in adipose (fat cells underneath the skin) and serum&#xD;
      (blood) samples. In addition, researchers hope to evaluate if/how the mother's weight has an&#xD;
      effect on the levels of antibiotics in the tissues (a group of similar cells).&#xD;
&#xD;
      This follow up study (prior study HS# 2009-7015 at UCI) will enroll obese (Body Mass Index&#xD;
      (BMI) of 30-40) and morbidly obese (BMI &gt;40) women to receive an increased dose of&#xD;
      prophylactic cefazolin at time of scheduled cesarean delivery at both UCI and LBMMC.&#xD;
      Researchers hope to enroll a total of 35 women overall.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:&#xD;
&#xD;
      This is a follow-up to the original pilot study (HS# 2009-7015 at UCI/587-08 at LBMMC). This&#xD;
      study is also designed to be a prospective, non-randomized, non-blinded trial of the effects&#xD;
      of obesity on adequacy of antimicrobial (cefazolin) concentrations with increased doses (from&#xD;
      2 grams to 3 grams) of preoperative prophylactic antibiotics within adipose tissues at the&#xD;
      time of cesarean delivery.&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
      â€¢ Patients at term (&gt;37 weeks) undergoing a cesarean delivery at LBMMC and UCI.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  pre-gestational diabetes&#xD;
&#xD;
        -  chronic hypertension&#xD;
&#xD;
        -  collagen vascular disease&#xD;
&#xD;
        -  renal impairment&#xD;
&#xD;
        -  multiple gestation&#xD;
&#xD;
        -  contraindications to cefazolin administration (known anaphylactic reaction to&#xD;
           penicillin's or known cephalosporin allergy)&#xD;
&#xD;
        -  any exposure to cephalosporins in one week prior to cesarean section&#xD;
&#xD;
        -  need for emergent cesarean delivery or diagnosis of chorioamnionitis&#xD;
&#xD;
      Study Procedure:&#xD;
&#xD;
      All patients requiring cesarean delivery under non-emergent circumstances, as determined by&#xD;
      their physician, will be approached for participation in study by co-investigators. They will&#xD;
      be approached on Labor and Delivery during their intake evaluation on the day of their&#xD;
      scheduled procedure. Based on published literature and preliminary power analysis we expect&#xD;
      that each of the 2 study groups will need 1414 subjects to demonstrate statistically&#xD;
      significant difference in antibiotic concentrations within adipose tissue. The two groups&#xD;
      will consist of:&#xD;
&#xD;
        1. OBESE GROUP (BMI 30-40)&#xD;
&#xD;
        2. MORBIDLY OBESE GROUP (BMI &gt;40)&#xD;
&#xD;
             1. All subjects will receive cefazolin at least 30, but no more than 60 minutes prior&#xD;
                to skin incision.&#xD;
&#xD;
             2. At the time of cesarean delivery, the following tissue samples will be collected:&#xD;
&#xD;
                  -  adipose tissue immediately following skin incision (prior to incision of the&#xD;
                     fascia) and&#xD;
&#xD;
                  -  adipose tissue prior to skin closure&#xD;
&#xD;
                  -  serum sample after skin incision but prior to completion of the operative&#xD;
                     procedure&#xD;
&#xD;
      Approximately 2 grams of tissue sampled from each site and 5 cc of blood will be required for&#xD;
      analysis.&#xD;
&#xD;
      All samples will be collected by Dr. Swank, Dr. Wing or a physician who had previously been&#xD;
      proctored in the proper tissue collecting techniques by either of the above mentioned&#xD;
      investigators. Upon collection, tissue specimens will be blotted to remove residual blood and&#xD;
      debris, weighed, and placed in a freezer (-80'C) until analysis. Serum samples will be drawn&#xD;
      into red top tubes and immediately placed on wet ice. Immediately following completion of the&#xD;
      surgery, they will then be centrifuged for 10 minutes at 3G (3200 rpm) and placed in a locked&#xD;
      -80'C freezer until analysis.&#xD;
&#xD;
      Tissue and serum samples will then be sent to David P. Nicolau, PhD, FCCP, FIDSA, at the&#xD;
      Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut.&#xD;
      Samples will be batched and sent all together at the completion of study enrollment. Dr.&#xD;
      Swank and the study nurse will be responsible for securely packing samples on dry ice and&#xD;
      overnight shipping them to Dr. Nicolau. Once with Dr. Nicolau, the tissue samples will be&#xD;
      homogenized and analyzed to determine zones of inhibition. The Cefazolin concentrations will&#xD;
      be determined in the serum samples using a previously validated high-performance liquid&#xD;
      chromatography method. 16 Tissues and serum will be sent without direct identifiers. Dr.&#xD;
      Nicolau will not have access to the identity of the research subjects providing the samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of Minimal Inhibitory Concentrations Within Adipose and Serum Sampled at Time of Cesarean Delivery</measure>
    <time_frame>Each participant is to be observed per routine operative and post-operative guidelines, inpatient for 3-4 days.</time_frame>
    <description>Primary Objective:&#xD;
To assess the effects of increased prophylactic doses of Cefazolin in the obese and morbidly obese populations undergoing cesarean delivery. Effects will be defined as the ability to reach the minimal inhibitory concentrations for gram-positive and gram-negative organisms in adipose tissue and serum at time of skin incision and skin closure as defined by the Clinical and Laboratory Standards Institute</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Obesity</condition>
  <condition>Obesity, Morbid</condition>
  <condition>Pregnancy</condition>
  <condition>Infection; Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects undergoing elective term cesarean delivery will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.</description>
    <arm_group_label>Cefazolin</arm_group_label>
    <other_name>Ancef</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients at term (&gt;37 weeks) undergoing a cesarean delivery at Women's Pavilion at&#xD;
             Miller Children's Hospital and University of California, Irvine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pre-gestational diabetes&#xD;
&#xD;
          -  chronic hypertension&#xD;
&#xD;
          -  collagen vascular disease&#xD;
&#xD;
          -  renal impairment&#xD;
&#xD;
          -  multiple gestation&#xD;
&#xD;
          -  contraindications to Cefazolin administration (known anaphylactic reaction to&#xD;
             penicillin's or known cephalosporin allergy)&#xD;
&#xD;
          -  any exposure to cephalosporins in one week prior to cesarean section&#xD;
&#xD;
          -  need for emergent cesarean delivery or diagnosis of chorioamnionitis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer McNulty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MemorialCare Center for Women at Miller Children's Hospital Long Beach and Long Beach Memorial Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah A Wing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morgan Swank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MemorialCare Center for Women at Miller Children's Hospital Long Beach and Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic Prophylaxis</keyword>
  <keyword>Obesity</keyword>
  <keyword>Obesity, Morbid</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Infection; Cesarean Section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3g Cefazolin</title>
          <description>Prospective cohort obese women receiving 3g prophylactic cefazolin 30-60 minutes prior to scheduled cesarean delivery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Obese (BMI 30-40kg/m^2)</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Extremely Obese (BMI &gt;40kg/m^2)</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3g Cefazolin</title>
          <description>3g IV cefazolin given 30-60 minutes prior to skin incision</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" lower_limit="26.5" upper_limit="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>preoperative hemoglobin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.0" lower_limit="11.4" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average BMI</title>
          <population>these data were analyzed by BMI category, 14 obese and 14 extremely obese.</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Obese, BMI 30-40kg/m^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.82" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely Obese, BMI &gt;40kg/m^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.03" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Achievement of Minimal Inhibitory Concentrations Within Adipose and Serum Sampled at Time of Cesarean Delivery</title>
        <description>Primary Objective:&#xD;
To assess the effects of increased prophylactic doses of Cefazolin in the obese and morbidly obese populations undergoing cesarean delivery. Effects will be defined as the ability to reach the minimal inhibitory concentrations for gram-positive and gram-negative organisms in adipose tissue and serum at time of skin incision and skin closure as defined by the Clinical and Laboratory Standards Institute</description>
        <time_frame>Each participant is to be observed per routine operative and post-operative guidelines, inpatient for 3-4 days.</time_frame>
        <population>participants were divided in BMI categories, 30-40kg/m2 and &gt;40kg/m2.</population>
        <group_list>
          <group group_id="O1">
            <title>3g Cefazolin</title>
            <description>Prospective cohort obese women receiving 3g prophylactic cefazolin 30-60 minutes prior to scheduled cesarean delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of Minimal Inhibitory Concentrations Within Adipose and Serum Sampled at Time of Cesarean Delivery</title>
          <description>Primary Objective:&#xD;
To assess the effects of increased prophylactic doses of Cefazolin in the obese and morbidly obese populations undergoing cesarean delivery. Effects will be defined as the ability to reach the minimal inhibitory concentrations for gram-positive and gram-negative organisms in adipose tissue and serum at time of skin incision and skin closure as defined by the Clinical and Laboratory Standards Institute</description>
          <population>participants were divided in BMI categories, 30-40kg/m2 and &gt;40kg/m2.</population>
          <units>mg/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BMI 30-40 3g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="20.3" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMI &gt;40 3g</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="7.6" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To detect the number of subjects who obtained a minimal inhibitory concentration (&gt;4mg/ml) following increased 3g dose of cefazolin. Compare this number to the historical cohort who had received 2g of cefazolin (standard dosing)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>we used t-test on the regression coefficient for the group indicator to test for differences in means categorical variables were evaluated using fisher's exact test of association linear regression for log transformed start adipose concentrations were calculated by dose specific group</non_inferiority_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>3g Cefazolin</title>
          <description>3g cefazolin provided via IV push 30-60 minutes prior to skin incision</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Morgan Swank</name_or_title>
      <organization>Memorial Care</organization>
      <phone>5624808460</phone>
      <email>morganswankmd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

